A novel mRNA vaccine, SYS6006, against SARS-CoV-2
The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven to induce strong humoral and cellular immunity against SARS-CoV-2. Here, we studied the immunogenicity and protection efficacy of a novel mRN...
Saved in:
| Published in | Frontiers in immunology Vol. 13; p. 1051576 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
05.01.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven to induce strong humoral and cellular immunity against SARS-CoV-2. Here, we studied the immunogenicity and protection efficacy of a novel mRNA vaccine SYS6006. High expression of mRNA molecules in 293T cells was detected. The initial and boost immunization with a 21-day interval was determined as an optimal strategy for SYS6006. Two rounds of immunization with SYS6006 were able to induce the neutralizing antibodies against the SARS-CoV-2 wild-type (WT) strain, and Delta and Omicron BA.2 variants in mice or non-human primates (NHPs). A3
rd
round of vaccination could further enhance the titers of neutralization against Delta and Omicron variants.
In vitro
ELISpot assay showed that SYS6006 could induce memory B cell and T cell immunities specifically against SARS-CoV-2 in mice. FACS analysis indicated that SYS6006 successfully induced SARS-CoV-2-specific activation of T follicular helper cell (Tfh) and Th1 cell, and did not induce CD4
+
Th2 response in NHPs. SYS6006 vaccine could significantly reduce the viral RNA loads and prevent lung lesions in Delta variant infected hACE2 transgenic mice. Therefore, SYS6006 could provide significant immune protection against SARS-CoV-2. |
|---|---|
| AbstractList | The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven to induce strong humoral and cellular immunity against SARS-CoV-2. Here, we studied the immunogenicity and protection efficacy of a novel mRNA vaccine SYS6006. High expression of mRNA molecules in 293T cells was detected. The initial and boost immunization with a 21-day interval was determined as an optimal strategy for SYS6006. Two rounds of immunization with SYS6006 were able to induce the neutralizing antibodies against the SARS-CoV-2 wild-type (WT) strain, and Delta and Omicron BA.2 variants in mice or non-human primates (NHPs). A3
round of vaccination could further enhance the titers of neutralization against Delta and Omicron variants.
ELISpot assay showed that SYS6006 could induce memory B cell and T cell immunities specifically against SARS-CoV-2 in mice. FACS analysis indicated that SYS6006 successfully induced SARS-CoV-2-specific activation of T follicular helper cell (Tfh) and Th1 cell, and did not induce CD4
Th2 response in NHPs. SYS6006 vaccine could significantly reduce the viral RNA loads and prevent lung lesions in Delta variant infected hACE2 transgenic mice. Therefore, SYS6006 could provide significant immune protection against SARS-CoV-2. The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven to induce strong humoral and cellular immunity against SARS-CoV-2. Here, we studied the immunogenicity and protection efficacy of a novel mRNA vaccine SYS6006. High expression of mRNA molecules in 293T cells was detected. The initial and boost immunization with a 21-day interval was determined as an optimal strategy for SYS6006. Two rounds of immunization with SYS6006 were able to induce the neutralizing antibodies against the SARS-CoV-2 wild-type (WT) strain, and Delta and Omicron BA.2 variants in mice or non-human primates (NHPs). A3rd round of vaccination could further enhance the titers of neutralization against Delta and Omicron variants. In vitro ELISpot assay showed that SYS6006 could induce memory B cell and T cell immunities specifically against SARS-CoV-2 in mice. FACS analysis indicated that SYS6006 successfully induced SARS-CoV-2-specific activation of T follicular helper cell (Tfh) and Th1 cell, and did not induce CD4+Th2 response in NHPs. SYS6006 vaccine could significantly reduce the viral RNA loads and prevent lung lesions in Delta variant infected hACE2 transgenic mice. Therefore, SYS6006 could provide significant immune protection against SARS-CoV-2. The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven to induce strong humoral and cellular immunity against SARS-CoV-2. Here, we studied the immunogenicity and protection efficacy of a novel mRNA vaccine SYS6006. High expression of mRNA molecules in 293T cells was detected. The initial and boost immunization with a 21-day interval was determined as an optimal strategy for SYS6006. Two rounds of immunization with SYS6006 were able to induce the neutralizing antibodies against the SARS-CoV-2 wild-type (WT) strain, and Delta and Omicron BA.2 variants in mice or non-human primates (NHPs). A3 rd round of vaccination could further enhance the titers of neutralization against Delta and Omicron variants. In vitro ELISpot assay showed that SYS6006 could induce memory B cell and T cell immunities specifically against SARS-CoV-2 in mice. FACS analysis indicated that SYS6006 successfully induced SARS-CoV-2-specific activation of T follicular helper cell (Tfh) and Th1 cell, and did not induce CD4 + Th2 response in NHPs. SYS6006 vaccine could significantly reduce the viral RNA loads and prevent lung lesions in Delta variant infected hACE2 transgenic mice. Therefore, SYS6006 could provide significant immune protection against SARS-CoV-2. The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven to induce strong humoral and cellular immunity against SARS-CoV-2. Here, we studied the immunogenicity and protection efficacy of a novel mRNA vaccine SYS6006. High expression of mRNA molecules in 293T cells was detected. The initial and boost immunization with a 21-day interval was determined as an optimal strategy for SYS6006. Two rounds of immunization with SYS6006 were able to induce the neutralizing antibodies against the SARS-CoV-2 wild-type (WT) strain, and Delta and Omicron BA.2 variants in mice or non-human primates (NHPs). A3rd round of vaccination could further enhance the titers of neutralization against Delta and Omicron variants. In vitro ELISpot assay showed that SYS6006 could induce memory B cell and T cell immunities specifically against SARS-CoV-2 in mice. FACS analysis indicated that SYS6006 successfully induced SARS-CoV-2-specific activation of T follicular helper cell (Tfh) and Th1 cell, and did not induce CD4+Th2 response in NHPs. SYS6006 vaccine could significantly reduce the viral RNA loads and prevent lung lesions in Delta variant infected hACE2 transgenic mice. Therefore, SYS6006 could provide significant immune protection against SARS-CoV-2.The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven to induce strong humoral and cellular immunity against SARS-CoV-2. Here, we studied the immunogenicity and protection efficacy of a novel mRNA vaccine SYS6006. High expression of mRNA molecules in 293T cells was detected. The initial and boost immunization with a 21-day interval was determined as an optimal strategy for SYS6006. Two rounds of immunization with SYS6006 were able to induce the neutralizing antibodies against the SARS-CoV-2 wild-type (WT) strain, and Delta and Omicron BA.2 variants in mice or non-human primates (NHPs). A3rd round of vaccination could further enhance the titers of neutralization against Delta and Omicron variants. In vitro ELISpot assay showed that SYS6006 could induce memory B cell and T cell immunities specifically against SARS-CoV-2 in mice. FACS analysis indicated that SYS6006 successfully induced SARS-CoV-2-specific activation of T follicular helper cell (Tfh) and Th1 cell, and did not induce CD4+Th2 response in NHPs. SYS6006 vaccine could significantly reduce the viral RNA loads and prevent lung lesions in Delta variant infected hACE2 transgenic mice. Therefore, SYS6006 could provide significant immune protection against SARS-CoV-2. |
| Author | Lei, Wenwen Xu, Ke Lv, Lu Kang, Bin Yang, Mengjie Sun, Yufei Zhang, Jing Yang, Hanyu Wu, Guizhen Wang, Yajuan Wang, Xiaolin Dan, Mo Lu, Yanli |
| AuthorAffiliation | 1 National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing , China 3 State Key Laboratory of Novel Pharmaceutical Preparations and Excipients, CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang, Hebei , China 2 CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang, Hebei , China |
| AuthorAffiliation_xml | – name: 3 State Key Laboratory of Novel Pharmaceutical Preparations and Excipients, CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang, Hebei , China – name: 2 CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang, Hebei , China – name: 1 National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing , China |
| Author_xml | – sequence: 1 givenname: Ke surname: Xu fullname: Xu, Ke – sequence: 2 givenname: Wenwen surname: Lei fullname: Lei, Wenwen – sequence: 3 givenname: Bin surname: Kang fullname: Kang, Bin – sequence: 4 givenname: Hanyu surname: Yang fullname: Yang, Hanyu – sequence: 5 givenname: Yajuan surname: Wang fullname: Wang, Yajuan – sequence: 6 givenname: Yanli surname: Lu fullname: Lu, Yanli – sequence: 7 givenname: Lu surname: Lv fullname: Lv, Lu – sequence: 8 givenname: Yufei surname: Sun fullname: Sun, Yufei – sequence: 9 givenname: Jing surname: Zhang fullname: Zhang, Jing – sequence: 10 givenname: Xiaolin surname: Wang fullname: Wang, Xiaolin – sequence: 11 givenname: Mengjie surname: Yang fullname: Yang, Mengjie – sequence: 12 givenname: Mo surname: Dan fullname: Dan, Mo – sequence: 13 givenname: Guizhen surname: Wu fullname: Wu, Guizhen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36685587$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kVtLHDEcxUNR1Fq_QB_KPPbBWXO_vBSWxVpBKrhV8Cnkuo3MTOxkdqHf3hl3K9oH85KQnPM7f3I-gr0udwGAzwjOCJHqLKa2Xc8wxHiGIENM8A_gCHFOa4Ix3Xt1PgQnpTzAcVFFCGEH4JBwLhmT4gigedXlTWiq9ubnvNoY51IXTqvl_ZJDyE8rszKpK0O1nN8s60W-q_EnsB9NU8LJbj8Gt9_Pfy1-1FfXF5eL-VXtKJdDLSiVEjIbhRSGEyyctcpL7J3CXljLePSeEx4V8zFGzEOE1FLBoQiECESOweWW67N50I99ak3_V2eT9PNF7lfa9ENyTdCEKkWQQyI4Tj1iUjqBlaUGSYGhZSPr25b1uLZt8C50Q2-aN9C3L136rVd5o5Uc0Wwa5usO0Oc_61AG3abiQtOYLuR10VhwKRGHZMr68jrrJeTfn48CvBW4PpfSh_giQVBP3ernbvXUrd51O5rkfyaXBjOkPM2bmvesT2Sapfk |
| CitedBy_id | crossref_primary_10_1089_blr_2023_29325_yd crossref_primary_10_1360_TB_2023_0629 crossref_primary_10_1371_journal_ppat_1012116 crossref_primary_10_3389_fimmu_2024_1416375 crossref_primary_10_3389_fimmu_2025_1524317 crossref_primary_10_1007_s40265_024_02013_8 crossref_primary_10_1016_j_vaccine_2024_01_098 crossref_primary_10_1080_22221751_2024_2320913 crossref_primary_10_3390_vaccines12060579 crossref_primary_10_1093_lifemeta_load019 crossref_primary_10_3390_biotech13030022 crossref_primary_10_1002_biot_202300658 crossref_primary_10_1002_jmv_29542 crossref_primary_10_1007_s11684_023_1034_6 crossref_primary_10_1016_j_vaccine_2024_03_005 crossref_primary_10_1038_s41467_024_51056_8 crossref_primary_10_1080_21645515_2023_2285089 crossref_primary_10_1002_adma_202308029 crossref_primary_10_1007_s40820_025_01665_9 crossref_primary_10_3390_vaccines12010030 crossref_primary_10_3389_fcimb_2024_1468775 |
| Cites_doi | 10.1038/s41586-021-03275-y 10.1056/NEJMoa2110345 10.3389/fimmu.2021.772240 10.1016/j.cell.2021.12.033 10.1007/s12098-020-03475-w 10.12659/MSM.933622 10.3390/cells10020206 10.1093/infdis/jiab556 10.1016/j.immuni.2010.12.012 10.1016/j.cell.2020.02.058 10.1038/s41573-021-00283-5 10.1016/j.cell.2020.07.024 10.1016/j.immuni.2021.08.001 10.1056/NEJMc2119912 10.1056/NEJMoa2024671 10.1016/j.jviromet.2013.05.015 10.1038/s41467-020-20642-x 10.1016/j.cell.2020.05.042 10.1016/j.immuni.2013.08.031 10.1038/s41591-021-01527-y 10.1056/NEJMoa2022483 10.1038/s41586-021-03738-2 10.1158/0008-5472.CAN-18-0455 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Xu, Lei, Kang, Yang, Wang, Lu, Lv, Sun, Zhang, Wang, Yang, Dan and Wu. Copyright © 2023 Xu, Lei, Kang, Yang, Wang, Lu, Lv, Sun, Zhang, Wang, Yang, Dan and Wu 2023 Xu, Lei, Kang, Yang, Wang, Lu, Lv, Sun, Zhang, Wang, Yang, Dan and Wu |
| Copyright_xml | – notice: Copyright © 2023 Xu, Lei, Kang, Yang, Wang, Lu, Lv, Sun, Zhang, Wang, Yang, Dan and Wu. – notice: Copyright © 2023 Xu, Lei, Kang, Yang, Wang, Lu, Lv, Sun, Zhang, Wang, Yang, Dan and Wu 2023 Xu, Lei, Kang, Yang, Wang, Lu, Lv, Sun, Zhang, Wang, Yang, Dan and Wu |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2022.1051576 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_349931c17ec64d1588c729b4a18720b5 PMC9849951 36685587 10_3389_fimmu_2022_1051576 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c468t-7448805bf787a6327cbb9d82dc92d7bb56fdd636f95dfff26ef04b47607e33713 |
| IEDL.DBID | M48 |
| ISSN | 1664-3224 |
| IngestDate | Wed Aug 27 01:32:57 EDT 2025 Thu Aug 21 18:38:51 EDT 2025 Fri Jul 11 09:39:30 EDT 2025 Thu Apr 03 07:07:24 EDT 2025 Tue Jul 01 02:13:35 EDT 2025 Thu Apr 24 22:56:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | T cell immunity Omicron variant neutralizing antibody SARS-CoV-2 spike protein mRNA vaccine |
| Language | English |
| License | Copyright © 2023 Xu, Lei, Kang, Yang, Wang, Lu, Lv, Sun, Zhang, Wang, Yang, Dan and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c468t-7448805bf787a6327cbb9d82dc92d7bb56fdd636f95dfff26ef04b47607e33713 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Jingxin Li, Jiangsu Provincial Center for Disease Control And Prevention, China Reviewed by: Ivan Odak, Hannover Medical School, Germany; Jungang Chen, University of Arkansas for Medical Sciences, United States These authors have contributed equally to this work This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2022.1051576 |
| PMID | 36685587 |
| PQID | 2768816035 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_349931c17ec64d1588c729b4a18720b5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9849951 proquest_miscellaneous_2768816035 pubmed_primary_36685587 crossref_primary_10_3389_fimmu_2022_1051576 crossref_citationtrail_10_3389_fimmu_2022_1051576 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-05 |
| PublicationDateYYYYMMDD | 2023-01-05 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2023 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Dutta (B5) 2020; 87 Corbett (B14) 2020; 383 Bosnjak (B19) 2021; 12 Smither (B10) 2013; 193 Hou (B21) 2020; 182 Garcia-Beltran (B23) 2022; 185 Morita (B16) 2011; 34 Aleem (B2) 2022 Parums (B1) 2021; 27 Walls (B3) 2020; 181 Chilamakuri (B4) 2021; 10 Zhang (B22) 2020; 182 Saciuk (B18) 2022; 225 Chaudhary (B8) 2021; 20 Turner (B9) 2021; 596 Painter (B20) 2021; 54 Locci (B15) 2013; 39 Pajon (B24) 2022; 386 Thomas (B7) 2021; 385 Shaan Lakshmanappa (B17) 2021; 12 Choi (B6) 2021; 27 Jackson (B13) 2020; 383 Vogel (B12) 2021; 592 Ning (B11) 2018; 78 |
| References_xml | – volume: 592 year: 2021 ident: B12 article-title: BNT162b vaccines protect rhesus macaques from SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-021-03275-y – volume: 385 year: 2021 ident: B7 article-title: Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months publication-title: N Engl J Med doi: 10.1056/NEJMoa2110345 – volume: 12 year: 2021 ident: B19 article-title: Intranasal delivery of MVA vector vaccine induces effective pulmonary immunity against SARS-CoV-2 in rodents publication-title: Front Immunol doi: 10.3389/fimmu.2021.772240 – volume: 185 start-page: 457 year: 2022 ident: B23 article-title: mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant publication-title: Cell doi: 10.1016/j.cell.2021.12.033 – volume: 87 year: 2020 ident: B5 article-title: Vaccine against covid-19 disease - present status of development publication-title: Indian J Pediatr doi: 10.1007/s12098-020-03475-w – volume: 27 year: 2021 ident: B1 article-title: Editorial: Revised world health organization (WHO) terminology for variants of concern and variants of interest of SARS-CoV-2 publication-title: Med Sci Monit doi: 10.12659/MSM.933622 – volume-title: Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19) year: 2022 ident: B2 – volume: 10 start-page: 206 year: 2021 ident: B4 article-title: COVID-19: Characteristics and therapeutics publication-title: Cells doi: 10.3390/cells10020206 – volume: 225 year: 2022 ident: B18 article-title: Effectiveness of a third dose of BNT162b2 mRNA vaccine publication-title: J Infect Dis doi: 10.1093/infdis/jiab556 – volume: 34 year: 2011 ident: B16 article-title: Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion publication-title: Immunity doi: 10.1016/j.immuni.2010.12.012 – volume: 181 start-page: 281 year: 2020 ident: B3 article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein publication-title: Cell doi: 10.1016/j.cell.2020.02.058 – volume: 20 year: 2021 ident: B8 article-title: mRNA vaccines for infectious diseases: principles, delivery and clinical translation publication-title: Nat Rev Drug Discovery doi: 10.1038/s41573-021-00283-5 – volume: 182 start-page: 1271 year: 2020 ident: B22 article-title: A thermostable mRNA vaccine against COVID-19 publication-title: Cell doi: 10.1016/j.cell.2020.07.024 – volume: 54 start-page: 2133 year: 2021 ident: B20 article-title: Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination publication-title: Immunity doi: 10.1016/j.immuni.2021.08.001 – volume: 386 year: 2022 ident: B24 article-title: SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination publication-title: N Engl J Med doi: 10.1056/NEJMc2119912 – volume: 383 year: 2020 ident: B14 article-title: Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates publication-title: N Engl J Med doi: 10.1056/NEJMoa2024671 – volume: 193 year: 2013 ident: B10 article-title: Comparison of the plaque assay and 50% tissue culture infectious dose assay as methods for measuring filovirus infectivity publication-title: J Virol Methods doi: 10.1016/j.jviromet.2013.05.015 – volume: 12 start-page: 541 year: 2021 ident: B17 article-title: SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques publication-title: Nat Commun doi: 10.1038/s41467-020-20642-x – volume: 182 start-page: 429 year: 2020 ident: B21 article-title: SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract publication-title: Cell doi: 10.1016/j.cell.2020.05.042 – volume: 39 year: 2013 ident: B15 article-title: Human circulating PD-1+CXCR3-CXCR5+ memory tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses publication-title: Immunity doi: 10.1016/j.immuni.2013.08.031 – volume: 27 year: 2021 ident: B6 article-title: Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis publication-title: Nat Med doi: 10.1038/s41591-021-01527-y – volume: 383 year: 2020 ident: B13 article-title: An mRNA vaccine against SARS-CoV-2 - preliminary report publication-title: N Engl J Med doi: 10.1056/NEJMoa2022483 – volume: 596 year: 2021 ident: B9 article-title: SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses publication-title: Nature doi: 10.1038/s41586-021-03738-2 – volume: 78 year: 2018 ident: B11 article-title: A novel microtubule inhibitor overcomes multidrug resistance in tumors publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-18-0455 |
| SSID | ssj0000493335 |
| Score | 2.4669614 |
| Snippet | The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1051576 |
| SubjectTerms | Animals COVID-19 - prevention & control Immunization Immunology Mice Mice, Transgenic mRNA vaccine neutralizing antibody Omicron variant SARS-CoV-2 spike protein T cell immunity |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9tAEF1KINBLadMvN01QobdaRPu9OjomIRSaQ1yX9LTsZ-sSyyGxDf33nZEUY5fSXnqVVmg0o2Hf067eI-S91M4Inzi6lwFBydmVtZK-9IkllYKg2uGPwp8u1cVUfLyW11tWX7gnrJMH7hJ3wgGScxqoTkGJSKUxAfCgF44azSrfqpfCnLdFpn50uJdzLru_ZICF1Sd5Np-vgA8yhta2VKLIyNZM1Ar2_wll_r5Zcmv2OX9KnvSwsRh14T4jj1JzQPY7I8mfzwkdFc1inW6K-dXlqFi7gMvlw2LydQJIQw0L983NAAcWk9HVpBwvvpTsBZmen30eX5S9GUIZhDLLUgtsNekzdJhTnOngfR0Ni6FmUXsvVY5RcZVrGXPOTKVcCS-0qnTiHKjoS7LXLJr0mhS-htYIoc5JBBGD8hWLqGtWIfqJzgwIfUiMDb1SOBpW3FhgDJhM2ybTYjJtn8wB-bC55rbTyfjr6FPM92Ykaly3B6Dytq-8_VflB-TdQ7Us9AQudLgmLVb3lgGHMuifDWNeddXb3IorBc9q9IDonbruxLJ7ppl9b3W3awMRSfrmfwR_SB6jcX37MUe-JXvLu1U6Aniz9Mftm_wLP43yqQ priority: 102 providerName: Directory of Open Access Journals |
| Title | A novel mRNA vaccine, SYS6006, against SARS-CoV-2 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36685587 https://www.proquest.com/docview/2768816035 https://pubmed.ncbi.nlm.nih.gov/PMC9849951 https://doaj.org/article/349931c17ec64d1588c729b4a18720b5 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6VIiQuiDfhURmJGzV43-sDQqGiVEjtoSEonKx9lqDEhjSp6L9nxnYiggonLj7Yu_LujEfzfbve-Qh5IbU1wkWO6mVAUFKyeamky11kUUUvqLZ4UPj4RB2NxceJnOyQtdxRb8DzK6kd6kmNF7NXP39cvoWAf4OME_Lt6zSdz1dA9RhD1VoKCPoauQ6ZSaOiwXEP9791aJhzLruzM3_pupWf2jL-V2HPP3-h_C0nHd4mt3owmQ07798hO7G-S2508pKX9wgdZnVzEWfZ_PRkmF1Yj5vo-9noywjwh9rP7JmdAjrMRsPTUX7QfM7ZfTI-fP_p4CjvJRJyL5RZ5lpgAEqXIO6s4kx758pgWPAlC9o5qVIIiqtUypBSYiqmQjihVaEj50BQH5DduqnjI5K5EgLG-zJF4UXwyhUsYLWzAjFRsGZA6Nowle_rh6OMxawCHoHGrFpjVmjMqjfmgLzc9PneVc_4Z-t3aO9NS6x83d5oFmdVH0gVB4rGqac6eiUClcZ44AdOWGo0K5wckOdrb1UQKbj9YevYrM4rBszKoKo2tHnYeW_zKq4UzNXoAdFbft0ay_aTevq1rcZdGhiRpI__x-CfkJsoZ98u8cinZHe5WMVnAHqWbq9dLIDrhwnda7_qX1Eo_dI |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+mRNA+vaccine%2C+SYS6006%2C+against+SARS-CoV-2&rft.jtitle=Frontiers+in+immunology&rft.au=Ke+Xu&rft.au=Wenwen+Lei&rft.au=Bin+Kang&rft.au=Bin+Kang&rft.date=2023-01-05&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.1051576&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_349931c17ec64d1588c729b4a18720b5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |